Untitled chapter

Exogenous testosterone shuts the axis down within days. The pituitary stops releasing LH and FSH because it tastes a 40-year-old level of testosterone in the blood and concludes its job is done. Leydig cells go quiet. Intratesticular testosterone — which runs at concentrations 50-100x serum levels and drives spermatogenesis, pregnenolone, and DHEA — collapses. Testicular volume shrinks. The neurosteroid pathway that converts pregnenolone into the entire cascade of downstream hormones goes dark. This is what TRT does to the upstream signal, and it's what Phase 1 of this Path is engineered to prevent.

The fix is not "more testosterone." The fix is keeping the signal alive at the level above where TRT suppresses it. There are two upstream levers — the pituitary (GnRH receptors, where Gonadorelin acts) and the hypothalamus (kisspeptin neurons, where Kisspeptin-10 acts). Phase 1 deploys both. Four weeks. Specific doses. Specific timing tied to your TRT injection rhythm.

What's actually happening at the cellular level

GnRH is released from the hypothalamus in pulses — not continuously. The pituitary's GnRH receptors are designed to respond to pulsatile signal; continuous exposure desensitizes them and shuts LH/FSH output down. This is why Gonadorelin protocols emphasize frequency and small doses over large boluses, and why pulsatile dosing is the practitioner-preferred pattern. The peptide corpus is explicit: too much, too fast, "100% desensitizes your Leydig cells and hurts response." Conservative start, titrate up only if needed.

Kisspeptin sits one floor higher in the building. Kisspeptin neurons in the hypothalamus are the upstream trigger for GnRH release itself — they are the metronome that tells GnRH neurons when to fire. The substrate describes Kisspeptin-10 (the synthesized short-chain version of the larger native 54-amino-acid peptide) as acting "even higher up the cascade" than Gonadorelin. The advantage of starting at kisspeptin is that you're not bypassing the hypothalamus the way Gonadorelin does — you're restoring the physiological signal at its origin. The disadvantage is that the human-protocol evidence base is thinner. Both compounds are Expert-tier; kisspeptin trends toward Experimental for some indications.

The third lever in Phase 1 is HCG. HCG is an LH analog — it binds Leydig cell LH receptors directly and tells them to produce intratesticular testosterone whether or not the pituitary signal is present. This is the lever that preserves testicular volume, spermatogenesis, and the neurosteroid pathway (pregnenolone → DHEA → downstream) that exogenous testosterone alone shuts down. The substrate is unambiguous: HCG is "non-negotiable on TRT if fertility is even a remote consideration," and "the 'cost' of skipping HCG is silent testicular shutdown that becomes increasingly difficult to reverse the longer it runs."

You stack all three because they hit different nodes. Kisspeptin restores the hypothalamic metronome. Gonadorelin keeps the pituitary GnRH receptors exercised. HCG maintains the testicle itself. Removing any one of them leaves a gap in the cascade.

Phase 1 Protocol (Week 1-4)

Reconstitution math, abbreviated: a 5 mg Kisspeptin-10 vial in 2 mL BAC water gives 2,500 mcg/mL, so 50 mcg = 0.02 mL = 2 units on a 100-unit insulin syringe. A 10 mg Gonadorelin vial in 2 mL BAC water gives 5,000 mcg/mL, so 100 mcg = 2 units. HCG comes pre-measured; follow the vial's reconstitution instructions and dose by IU.

Inject Kisspeptin and Gonadorelin SubQ in the abdomen, abdomen-near, rotating clockwise around the navel staying at least 2 inches out. Do not mix in the same syringe. One syringe per injection. HCG can go SubQ in the same region but on different rotation points, or in the thigh.

What you should feel

The substrate cites specific milestones for Phase 1 axis-restart work, though responses are interindividual and TRT-baseline dependent:

• Week 1: Often nothing perceptible. The signaling cascade is restarting; downstream effects lag. Track injection-site tolerance and morning energy.
• Week 2: Testicular volume often perceptibly increases by end of week 2 in users who had visible atrophy. Morning erections may return or strengthen — this is the cleanest early signal of upstream axis restoration.
• Week 3-4: Libido and ejaculate volume typically respond by the end of Week 3 in responders. Mood and cognitive clarity often follow, though these are confounded by E2 trajectory — if Gonadorelin/HCG over-stimulate aromatization, mood can dip.

If you see zero testicular response by end of Week 3 and compliance is verified, the issue is usually dose (too low) or timing (HCG not bracketing TRT days). Adjust before adding compounds.

What's NOT happening yet

• Spermatogenesis is not restored in 4 weeks. Sperm cycle is ~74 days. If fertility is the goal, Phase 1 is the foundation, not the result. Semen analysis at Week 12+ is the lagging indicator that matters.
• Endogenous LH/FSH self-sufficiency is not the goal of Phase 1. You're keeping the receptors exercised, not restarting unassisted production. That conversation belongs to a PCT protocol, not TRT optimization.
• Estradiol is moving. HCG aromatizes. Gonadorelin stimulates pulsatile LH which drives endogenous T which aromatizes. Phase 1 raises total aromatization load. Plan for E2 bloodwork at Week 4 and have an AI strategy ready if E2 climbs above your target range.
• Pregnenolone and DHEA recovery is slower than the immediate testicular markers. These neurosteroids rebuild over weeks, and bloodwork at Week 4 is too early for clean signal. Re-test at Week 8.
• "Feeling better on TRT" is not the Phase 1 endpoint. The endpoint is preserved testicular volume, restored intratesticular signaling, and a primed axis that can be layered with Phase 2 (Week 5-10) without resistance.

The peptide corpus is consistent on conservative starts and pulsatile rhythm — start low, track, titrate only on signal.